Soluble CD146, a novel endothelial market, is related to the severity of liver disease.

Doctoral Dissertation uoadl:1305554 726 Read counter

Unit:
Τομέας Παθολογίας
Library of the School of Health Sciences
Deposit date:
2015-01-09
Year:
2014
Author:
Νομικού Ευφροσύνη
Dissertation committee:
καθηγητής Σ.Ντουράκης,επικ.καθηγήτρια Α.Αλεξοπούλου,αναπλ.καθηγήτρια Α.Φιλιώτου
Original Title:
To διαλυτό CD146 ως πρωτότυπος ενδοθηλιακός δείκτης, σχετίζεται με την βαρύτητα της ηπατικής νόσου και την εξέλιξη σε κίρρωση
Languages:
Greek
Translated title:
Soluble CD146, a novel endothelial market, is related to the severity of liver disease.
Summary:
Summary
Background: Angiogenesis and inflammation have been involved in the progression
of fibrosis in patients with chronic liver disease (CLD). Soluble CD146
(sCD146), a biomarker which was recently characterized as a novel component of
the endothelial junction is implicated in endothelial proliferation.
Aim: To evaluate the performance of sCD146 in assessing liver fibrosis and
cirrhosis and determine if its levels are related to the severity of liver
disease in patients with cirrhosis.
Methods: sCD146 levels were determined by a commercially available
immunoenzymatic technique in sixty-two consecutive patients with cirrhosis,
forty-three patients with CLD and twenty-seven healthy controls.
Results: Patients with cirrhosis compared to non-cirrhotics with CLD had a
higher median sCD146 concentration (639 vs 317 ng/ml). In receiver operating
characteristic (ROC) curve analysis, the cut-off of 412 ng/ml showed a
sensitivity of 78% and a specificity of 75% for diagnosis of cirrhosis,
offering good diagnostic accuracy (AUROC:0.838). Patients with compensated
compared to those with decompensated cirrhosis had a lower median sCD146
concentration (399 vs 848 ng/ml, respectively). A cut-off of 534 ng/ml offered
a sensitivity of 83% and a specificity of 78% for differentiating compensated
from decompensated cirrhosis (AUROC:0.866). Furthermore, in cirrhotics, sCD146
correlated positively with AST, bilirubin levels and most importantly with INR
and MELD (r=0.648, P<0.001 and r=0.567, P<0.001, respectively).
Conclusion: sCD146 can be used as a surrogate, inexpensive biomarker for the
diagnosis of cirrhosis. It is also well correlated with severity of liver
disease in cirrhotic patients. Further studies are needed to define its role in
clinical practice.
Keywords:
Angiogenesis, Cirrhosis, Endothelial marker, Soluble CD146
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
210
Number of pages:
167

document.pdf
2 MB
File access is restricted only to the intranet of UoA.